Monitoring kidney oxygen with NIRS in babies born before 30 weeks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will use near-infrared spectroscopy (NIRS) to measure renal tissue oxygen saturation (SrSO2) in premature infants born before 30 weeks gestation. Continuous or repeated NIRS readings will be recorded in the NICU to characterize oxygenation patterns over time. Investigators will analyze prenatal and postnatal risk factors for acute kidney injury and compare outcomes such as death, length of stay, and prolonged mechanical ventilation. Infants with major congenital kidney anomalies or those too small/immature for safe monitoring are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any neonate less than 30 weeks in gestational age
* Willingness and capacity of both adult parents/guardians to sign consent

Exclusion Criteria:

* An infant with known congenital anomalies of the kidney (i.e., grade 4 or 5 vesicoureteral reflux (VUR), posterior urethral valves, moderate or severe hydronephrosis, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal agenesis or dysplasia)
* Age \>30 weeks gestational age
* Age \<24 weeks and \<500 grams (will be excluded due to sensitivity of skin in this vulnerable population).
* Clinician's decision that NIRS is not suitable due to the patient's clinical condition

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Sourabh Verma, MD — NYU Langone Health
• Study coordinator: Sourabh Verma, MD
• Email: sourabh.verma@nyulangone.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Coordinated Communication, Education, and Care Transitions After Acute Kidney Injury (CONNECT-AKI)

  This study tests whether a discharge summary template and a chat-based education program help adults with AKI understand their condition and follow up after leaving the hospital.

  Recruiting at 2 sites Northwell Health · Glen Oaks, New York and 1 other locations · NCT07626268

• Hamburg Acute Renal Injury (HARIS) cohort

  This project will follow adults hospitalized with AKI and a group of similar hospitalized patients without AKI to test which clinical factors and blood or urine markers predict recovery and longer-term kidney and cardiovascular problems.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07338669

• AST-120 (Kremezin) for kidney protection and slowing decline after acute kidney disease

  This study will test whether adding AST-120 (Kremezin) to standard care lowers protein-bound uremic toxins and helps slow kidney decline in adults recovering from acute kidney disease.

  Recruiting Phase 4 Chang Gung Memorial Hospital · Taoyuan · NCT07182422

• Comparing two medications to prevent kidney injury after major surgery

  This study is testing which medication, norepinephrine or phenylephrine, works better to prevent kidney injury in adults having major surgery.

  Recruiting at 10 sites Phase 4 University of California, San Francisco · San Francisco, California and 9 other locations · NCT06802224

• Evaluating the safety of Prismocitrate 18 for patients on continuous renal replacement therapy

  This study is testing if a new solution called Prismocitrate 18 is safe for patients on a special type of kidney treatment to help prevent blood clots during their therapy.

  Recruiting at 7 sites Phase 3 Vantive Health LLC · Birmingham, Alabama and 13 other locations · NCT05399537

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.